CN111202841A - 一种提高身体免疫力的中药组合物及其制备方法 - Google Patents
一种提高身体免疫力的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN111202841A CN111202841A CN202010281182.XA CN202010281182A CN111202841A CN 111202841 A CN111202841 A CN 111202841A CN 202010281182 A CN202010281182 A CN 202010281182A CN 111202841 A CN111202841 A CN 111202841A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000036039 immunity Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 79
- 239000002994 raw material Substances 0.000 claims abstract description 27
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 13
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 13
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 13
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 13
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 13
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 13
- 244000131360 Morinda citrifolia Species 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000017524 noni Nutrition 0.000 claims abstract description 13
- 239000001702 nutmeg Substances 0.000 claims abstract description 13
- 229940098295 nutmeg extract Drugs 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- 229940074777 tripotassium glycyrrhizinate Drugs 0.000 claims abstract description 13
- ZXHXYXSTAYNRLQ-DWJAGBRCSA-K tripotassium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4, Chemical compound [K+].[K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O ZXHXYXSTAYNRLQ-DWJAGBRCSA-K 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 238000003809 water extraction Methods 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000036541 health Effects 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 8
- 210000001835 viscera Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 208000007443 Neurasthenia Diseases 0.000 abstract description 3
- 206010003549 asthenia Diseases 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 2
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种提高身体免疫力的中药组合物及其制备方法,它包括以下重量份的原料组成:蛹虫草子实体提取物12‑25份,提皮石斛提取物10‑21份,灵芝提取物8‑16份,猴头菇提取物1‑12份,酸枣仁提取物1‑3份,诺丽果浆提取物1‑8份,胶原蛋白肽1‑6份,肉豆蔻提取物2‑4份,牛磺酸3‑4份,Y‑氨基丁酸0.1‑0.22份,甘草酸三钾0.03‑0.06份。本发明分别经过预处理、烘干、粉碎、有效成分的萃取喷雾干燥和消毒灭菌等处理后检测达标,即可包装并做成成品出厂,本发明采用新资源食品和药食同源原料的有效成分萃取,针对五脏六腑,气血亏虚,体质虚弱,疲劳乏力,身体机能免疫力低下,失眠多梦,神经衰弱脑疲劳,畏寒怕冷等从根源上彻底恢复健康,标本兼治,安全可靠等从根源上彻底恢复健康,标本兼治,安全可靠。
Description
技术领域
本发明涉及的是中药技术领域,具体涉及一种提高身体免疫力的中药组合物及其制备方法。
背景技术
当下人们身体健康问题和疾病的药物治疗统的解决方式存在的弊端:
人体的五脏六腑之间按照五行,彼此相生相克,只要其中一个器官不健康,就会连带着别的器官的影响,彼此关联,靠单一的对某个器官的治疗无法彻底,而且在用药的过程中,药物的副作用产生了对健康的2次影响,西药对肝肾的伤害负担更是明显。所以在药物的治疗中形成了矛盾性(不用不行,用了也不彻底,无法从根源本质上解决问题,从而成为恶性循环,而且后期的身体体能的恢复也成为问题,气血属于阴阳关系,那么阴消阳长或者阳长阴消,无非形成完整的阴阳平衡 ,当五脏六腑和气血得不到根本上的功能提高,人的整体机能以及免疫力就会下降,体质虚弱。是药三分毒,无法在控制治疗问题的同时去规避药物对健康的影响。因此既需要彻底根源的去解决问题,又要考虑整体性,还需要避免用药的同时带给健康的影响,一直以来都是专业和现实治疗中的矛盾!细胞毒药物:常用的有环磷酰胺、甲氨蝶呤、金独春等。它们往往副作用虽较多且较严重,多会引起消化道溃疡;肾上腺皮质激素:能明显地消除炎症以及炎症带来发热、疼痛等症状,但由于其并非根治药物,长期大量使用可诱发感染,骨质疏松,股骨头坏死,糖尿病,消化道溃疡,高血压,精神异常等。
综上所述,本发明研发了一种从根源调理五脏六腑气血功能,全面提高身体免疫力的中药组合物及其制备方法。
发明内容
针对现有技术上存在的不足,本发明目的是在于提供一种提高身体免疫力的中药组合物及其制备方法,采用新资源以及药食同源原料提取有效成分,分别经过预处理、烘干、粉碎、有效成分的萃取喷雾干燥,和消毒灭菌等处理后,检测达标,即可包装并做成成品出厂,安全可靠,效果显著。
为了实现上述目的,本发明是通过如下的技术方案来实现:一种提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物12-25份,提皮石斛提取物10-21份 ,灵芝提取物 8-16份,猴头菇提取物1-12份,酸枣仁提取物1-3份,诺丽果浆提取物1-8份,胶原蛋白肽1-6份,肉豆蔻提取物2-4份,牛磺酸3-4份, Y-氨基丁酸 0.1-0.22份,甘草酸三钾 0.03-0.06份。
作为优选,所述的提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物12份,提皮石斛提取物10份 ,灵芝提取物 8份,猴头菇提取物1份,酸枣仁提取物1份,诺丽果浆提取物1份,胶原蛋白肽1份,肉豆蔻提取物2份,牛磺酸3份, Y-氨基丁酸 0.1份,甘草酸三钾 0.03份。
作为优选,所述的提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物25份,提皮石斛提取物21份 ,灵芝提取物16份,猴头菇提取物12份,酸枣仁提取物3份,诺丽果浆提取物8份,胶原蛋白肽6份,肉豆蔻提取物4份,牛磺酸4份,Y-氨基丁酸 0.22份,甘草酸三钾 0.06份。
作为优选,所述的提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物18份,提皮石斛提取物16份 ,灵芝提取物 12份,猴头菇提取物6份,酸枣仁提取物2份,诺丽果浆提取物4份,胶原蛋白肽3份,肉豆蔻提取物3份,牛磺酸4份, Y-氨基丁酸 0.16份,甘草酸三钾 0.05份。
一种提高身体免疫力的中药组合物的制备方法,包括以下步骤:检选清洗原料后,进行热水浸提,完成后,用乙醇沉淀,留下多糖溶液,之后喷雾干燥;消毒灭菌检测合格后包装成品。
一种提高身体免疫力的中药组合物的制备方法,包括以下步骤::检选清洗原料后,水提三次,然后将三次的提取液混合在一起,进行加热浓缩,浓缩完成后,喷雾干燥成粉;消毒灭菌检测合格后包装成品。
一种提高身体免疫力的中药组合物的制备方法,将上述重量份的原料通过乙醇进行提取,提取之后再进行纯化。选料分别经过预处理、烘干、粉碎、有效成分的萃取,喷雾干燥和消毒灭菌处理后检测达标即可包装并做成品。
本发明的有益效果:
本发明采用新资源食品和药食同源原料的有效成分萃取,针对五脏六腑,气血亏虚,体质虚弱,疲劳乏力,身体机能免疫力低下,失眠多梦,神经衰弱,畏寒怕冷等从根源上彻底恢复健康,标本兼治,安全可靠,效果达到98.6%。以上疗效均优于现代医学及传统中医常规辩证治疗与保健。
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施方式,进一步阐述本发明。
本具体实施方式采用以下技术方案:一种提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物12-25份,提皮石斛提取物10-21份 ,灵芝提取物 8-16份,猴头菇提取物1-12份,酸枣仁提取物1-3份,诺丽果浆提取物1-8份,胶原蛋白肽1-6份,肉豆蔻提取物2-4份,牛磺酸3-4份, Y-氨基丁酸 0.1-0.22份,甘草酸三钾 0.03-0.06份。
一种提高身体免疫力的中药组合物的制备方法,包括以下步骤:检选清洗原料后,进行热水浸提,完成后,用乙醇沉淀,留下多糖溶液,之后喷雾干燥;消毒灭菌检测合格后包装成品。
一种提高身体免疫力的中药组合物的制备方法,包括以下步骤::检选清洗原料后,水提三次,然后将三次的提取液混合在一起,进行加热浓缩,浓缩完成后,喷雾干燥成粉;消毒灭菌检测合格后包装成品。
一种提高身体免疫力的中药组合物的制备方法,将上述重量份的原料通过乙醇进行提取,提取之后再进行纯化。选料分别经过预处理、烘干、粉碎、有效成分的萃取,喷雾干燥和消毒灭菌处理后检测达标即可包装并做成品。
本具体实施方式采用国家卫生部,卫计委,卫法监,国家食品安全局所批准的新资源食品(食品级安全无副作用,老少皆宜)和药食同源(有药物的作用功能同时又能达到食品的安全性,无毒副作用“空腹食之为食物,患者食之为药物”)所批准的原料,分别以下方式进行提取:
一、多糖类:检选清洗原料后,进行热水浸提、提前完成后,用乙醇沉淀,留下多糖溶液,之后喷雾干燥;
二、比例提取物:检选清洗原料后,水提三次,然后将三次的提取液混合在一起,进行加热浓缩,浓缩完成后,喷雾干燥成粉。
三、黄酮类 :乙醇进行提取,提取之后在进行纯化。选料分别经过预处理、烘干、粉碎、有效成分的萃取 喷雾干燥,和消毒灭菌等处理后检测达标,即可包装并做成成品出厂,安全可靠,效果显著。
本中药组合物可以通过口腔,脾胃,小肠直接吸收,针对五脏六腑,气血亏虚,体质虚弱,疲劳乏力,小孩发育不良,生长缓慢,身体机能免疫力低下,失眠多梦,神经衰弱脑疲劳,畏寒怕冷等从根源上彻底恢复健康,标本兼治,安全可靠,效果达到98.6%。本发明针对人的五脏六腑所引发的问题能有效的调整到健康水平,安全可靠、标本兼治,且治疗周期短。经验证以上疗效均大大优于现代医学及传统中医常规辩证治疗与保健。
实施例1:一种提高身体免疫力的中药组合物,包括以下重量克的原料组成:蛹虫草子实体提取物12克,提皮石斛提取物10克 ,灵芝提取物 8克,猴头菇提取物1克,酸枣仁提取物1克,诺丽果浆提取物1克,胶原蛋白肽1克,肉豆蔻提取物2克,牛磺酸3克, Y-氨基丁酸 0.1克,甘草酸三钾 0.03克。
实施例2:一种提高身体免疫力的中药组合物,包括以下重量克的原料组成:蛹虫草子实体提取物25克,提皮石斛提取物21克 ,灵芝提取物16克,猴头菇提取物12克,酸枣仁提取物3克,诺丽果浆提取物8克,胶原蛋白肽6克,肉豆蔻提取物4克,牛磺酸4克,Y-氨基丁酸 0.22克,甘草酸三钾 0.06克。
实施例3:一种提高身体免疫力的中药组合物,包括以下重量克的原料组成:蛹虫草子实体提取物18克,提皮石斛提取物16克 ,灵芝提取物 12克,猴头菇提取物6克,酸枣仁提取物2克,诺丽果浆提取物4克,胶原蛋白肽3克,肉豆蔻提取物3克,牛磺酸4克, Y-氨基丁酸 0.16克,甘草酸三钾 0.05克。
使用本中药组合的成功案例如下:
案例一:王女士,46岁,病史,失眠10多年,严重影响到健康和情绪,甚至有了轻度抑郁,经常感冒,调理三个月产生巨大改变,睡眠变得正常,精神状态和体质都得到了根源性的改变。
案例二:刘先生,58岁,畏寒怕冷,肝肾功能性问题,气血亏虚,经过朋友推荐来调理,经过半年的治疗彻底治愈至今没有复发过。
案例三:李女士,68岁,体质虚弱,气血亏虚,伴随咳嗽胃痛,始终反反复复,后来在病友的推荐下调理,过半年的治疗成功治愈,三年来没有再复发过。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (7)
1.一种提高身体免疫力的中药组合物,其特征在于,包括以下重量份的原料组成:蛹虫草子实体提取物12-25份,提皮石斛提取物10-21份 ,灵芝提取物 8-16份,猴头菇提取物1-12份,酸枣仁提取物1-3份,诺丽果浆提取物1-8份,胶原蛋白肽1-6份,肉豆蔻提取物2-4份,牛磺酸3-4份, Y-氨基丁酸 0.1-0.22份,甘草酸三钾 0.03-0.06份。
2.根据权利要求1所述的,其特征在于,所述的提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物12份,提皮石斛提取物10份 ,灵芝提取物 8份,猴头菇提取物1份,酸枣仁提取物1份,诺丽果浆提取物1份,胶原蛋白肽1份,肉豆蔻提取物2份,牛磺酸3份, Y-氨基丁酸 0.1份,甘草酸三钾 0.03份。
3.根据权利要求1所述的,其特征在于,所述的提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物25份,提皮石斛提取物21份 ,灵芝提取物16份,猴头菇提取物12份,酸枣仁提取物3份,诺丽果浆提取物8份,胶原蛋白肽6份,肉豆蔻提取物4份,牛磺酸4份,Y-氨基丁酸 0.22份,甘草酸三钾 0.06份。
4.根据权利要求1所述的,其特征在于,所述的提高身体免疫力的中药组合物,包括以下重量份的原料组成:蛹虫草子实体提取物18份,提皮石斛提取物16份 ,灵芝提取物 12份,猴头菇提取物6份,酸枣仁提取物2份,诺丽果浆提取物4份,胶原蛋白肽3份,肉豆蔻提取物3份,牛磺酸4份, Y-氨基丁酸 0.16份,甘草酸三钾 0.05份。
5.一种提高身体免疫力的中药组合物的制备方法,其特征在于,包括以下步骤:检选清洗原料后,进行热水浸提,完成后,用乙醇沉淀,留下多糖溶液,之后喷雾干燥;消毒灭菌检测合格后包装成品。
6.根据权利要求5所述的一种提高身体免疫力的中药组合物的制备方法,其特征在于,包括以下步骤::检选清洗原料后,水提三次,然后将三次的提取液混合在一起,进行加热浓缩,浓缩完成后,喷雾干燥成粉;消毒灭菌检测合格后包装成品。
7.根据权利要求5所述的一种提高身体免疫力的中药组合物的制备方法,其特征在于,将上述重量份的原料通过乙醇进行提取,提取之后再进行纯化;毒灭菌处理后检测达标即可包装并做成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010281182.XA CN111202841A (zh) | 2020-04-11 | 2020-04-11 | 一种提高身体免疫力的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010281182.XA CN111202841A (zh) | 2020-04-11 | 2020-04-11 | 一种提高身体免疫力的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111202841A true CN111202841A (zh) | 2020-05-29 |
Family
ID=70781910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010281182.XA Pending CN111202841A (zh) | 2020-04-11 | 2020-04-11 | 一种提高身体免疫力的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111202841A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115251401A (zh) * | 2022-06-17 | 2022-11-01 | 兆鑫堂(山东)生物科技有限公司 | 一种利于免疫力提升的胶原蛋白肽营养补充组合物及其用途 |
-
2020
- 2020-04-11 CN CN202010281182.XA patent/CN111202841A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115251401A (zh) * | 2022-06-17 | 2022-11-01 | 兆鑫堂(山东)生物科技有限公司 | 一种利于免疫力提升的胶原蛋白肽营养补充组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN110393781B (zh) | 一种治疗甲状腺结节的纯中药制剂及制备方法 | |
CN105362906A (zh) | 一种治疗儿童脾胃虚弱、饮食积滞证的中药及其制备方法 | |
CN104146299A (zh) | 一种能够增强免疫力的保健饮品 | |
CN111265650A (zh) | 一种新型中药组合物及其制备方法 | |
CN111202841A (zh) | 一种提高身体免疫力的中药组合物及其制备方法 | |
CN109806382B (zh) | 一种乌鸡肽的组合物及其在制备治疗痛经药品中的应用 | |
CN103191363B (zh) | 一种治疗小儿疳积的中药组合物及其制备方法 | |
CN105267711A (zh) | 一种用于治疗眩晕症的药物制剂 | |
CN111387382A (zh) | 一种食疗戒毒的饮料及其制备方法 | |
CN110692984A (zh) | 一种清除口腔异味的玫瑰花咀嚼片及其制备方法 | |
CN111228470A (zh) | 一种中药组合物及其制备方法 | |
CN116492420B (zh) | 一种治疗慢性阻塞性肺疾病稳定期的组合物及其制备方法、用途 | |
CN109125413A (zh) | 一种具有补肾壮阳作用的中药组合物制剂及其制备方法 | |
CN109091633B (zh) | 一种用于小儿反复呼吸道感染的组合物及制法和应用 | |
CN102641442B (zh) | 一种治疗复发性口疮的中药制剂 | |
CN101732648B (zh) | 一种治疗骨不连的药物 | |
CN100589841C (zh) | 一种治疗口腔病的中药贴及其制备方法 | |
CN104887856A (zh) | 一种治疗席汉氏综合征的内服药物及制备方法 | |
CN117205276A (zh) | 一种治疗儿童生长痛的组合物、制剂及制备方法和应用 | |
CN114159501A (zh) | 一种消石制剂及其制备方法 | |
CN111686126A (zh) | 一种治疗感冒、流感、消渴药物 | |
CN107441352A (zh) | 一种治疗癫痫疾病的中药 | |
CN104258361A (zh) | 一种治疗小儿哮喘的中药组合物 | |
CN113599423A (zh) | 一种治疗贫血的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200529 |